Research Information System
MICROCHEMICAL JOURNAL, 2025 (SCI-Expanded)
Nowadays, human epidermal growth factor receptor 2 (HER2) is a critical biomarker and therapeutic target in breast cancer, associated with aggressive tumor behavior and poor prognosis. Therefore, its accurate detection is essential for effective diagnosis and treatment planning. In this study, we developed a novel electrochemical immunosensor platform for the sensitive detection of HER2. The sensor surface was decorated with trimetallic Au@Pt@Ag-based nanoparticles (NPs) to enhance its electrochemical properties. A sponge-like Au@Ru nanozyme was employed as a signal label to further amplify the detection signal due to its superior catalytic activity. The immunosensor was constructed by sequentially modifying a screen-printed electrode with Au@Pt@Ag NPs, primary antibody, HER2 antigen, and Au@Ru-labeled secondary antibody. The optimal experimental conditions were established, including the incubation times for antibodies, HER2, as well as the concentration of Au@Ru nanozyme. Under these optimized conditions, the immunosensor exhibited a wide linear detection range from 0.5 to 1000 pg/mL with a low detection limit of 0.15 pg/mL using amperometry as the detection technique. The analytical performance of the sensor was validated by detecting HER2 in human serum samples, achieving high recovery rates and low relative standard deviations (RSDs). Additionally, the immunosensor demonstrated excellent reproducibility and stability, with RSD values below 5 % over 15 days of storage. Selectivity tests showed minimal interference from common proteins such as human serum albumin, C-reactive protein, and Interleukin-6. These results indicates that the developed immunosensor is highly sensitive, reliable, and suitable for future clinical applications in HER2 detection.